^
Association details:
| Biomarker: | KRAS wild-type |
|---|---|
| Cancer: | Ovarian Serous Adenocarcinoma |
| Drug: | avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) + VS-4718 (FAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3402 / 12 - In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancer
Published date:
03/15/2023
Excerpt:
...animals were treated with either vehicle control (CTRL), RAF/MEK clamp avutometinib (MEKi), FAK inhibitor VS-4718, or the combination (MEKi/FAKi)....Both the OVA(K)250 and PERIT(M)17 PDX models express wildtype KRAS and express RAF1 mutations at position 12641679 A>C, V207G….Combination MEKi/FAKi treatment resulted in improved overall survival (OS); median OS for combination or MEKi alone was not reached by 60 days.
